1차 출처 기록
결정급탑라인 결과
Theravance: 암프렐록세틴 3상 CYPRESS 시험, 2026년 1분기 톱라인 결과 발표 예정
Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine is now complete. Topline results are on track for Q1 2026. Company plans expedited NDA submission and priority review request if data are supportive.
핵심 사실
출처 발췌
EX-99.1 2 tm2530676d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update · YUPELRI ® net sales reached an all-time high of $71.4 million, recognized by Viatris, up 15% year-over-year 1 , and achieved record brand profitability · Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 · Company to host an ampreloxetine focused virtual Key Opinion Leader (KOL) event for investors on December 8, 2025 · TRELEGY year-to-date sales on track to achieve $50 million milestone in 2025 2 · Strong balance sheet with $333 million in cash and no debt DUBLIN, IRELAND – NOVEMBER 10, 2025 – Theravance Biopharma, Inc. (“Theravance Biopharma” or